AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries

Recruitingn/aAges 18 Years - 75 YearsAllThe First Affiliated Hospital with Nanjing Medicaโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is a single-center, prospective, controlled, diagnostic study. The study will be consecutive and is expected to enroll 100 patients with CCTA confirmed coronary calcified lesions. The purpose of this study was to compare the accuracy of novel Ferumoxytol-enhanced Cardiac Magnetic Resonance (Fe-CMR) and coronary CT angiography (CCTA) in detecting calcified coronary arteries, using coronary angiography (CAG) and optical coherence imaging (OCT) as gold standards.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age โ‰ฅ18 years, \<75 years; 2. Imaging specialists evaluate CCTA images taken within 30 days and report that calcification occupied one or more of the patient's vascular lumen at an angle of \>50% (using the coronary artery segmentation method recommended by the American Heart Association, including nine segments of the major branches of the coronary artery); 3. Patient who will undergo coronary angiography; 4. Patient with normal renal function or chronic renal insufficiency (CKD) stage 1-3; 5. Patient who signs the informed consent. Exclusion Criteria: 1. People who are allergic to iodine contrast media or have a history of allergy to iron or dextran or are allergic themselves; 2. Because of psychological (such as suffering from claustrophobic syndrome) or physical reasons (such as the presence of metal objects in the body) can not receive MRI examination; 3. suffering from terminal diseases (such as malignant tumors) or life expectancy \< 1 year; 4. Pregnant or lactating women; 5. People with limited hearing; 6. Patients with grade III-IV heart function; 7. Patients with a history of coronary artery stent implantation or coronary artery bypass; 8. Other iron agents are being used orally or intravenously; 9. Patients with hemosiderosis or hemochromatosis; 10. Patients with acute coronary syndrome; 11. Patients with hyperthyroidism; 12. Any other candidates deemed unsuitable by the researchers.
๐Ÿ’Š

What it tests

  • Superparamagnetic Iron Oxide Nanoparticles
๐Ÿ“

Where

1 site
First Affiliated Hospital of Nanjing Medical University
Nanjing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy